A data-mining study of the safety of the 20-valent pneumococcal conjugate vaccine in adults in the Vaccine Safety Datalink Journal Article uri icon
Overview
abstract
  • BACKGROUND: A 20-valent pneumococcal conjugate vaccine (PCV20) was approved for adults by the US Food and Drug Administration in 2021. We conducted a data-mining signal-identification analysis to assess possible adverse events after vaccination.
    METHODS: We included individuals aged ≥  19 years from ten Vaccine Safety Datalink sites who received PCV20 between June 2021 and October 2024 and had continuous medical coverage from ≥  400 days before through 84 days after vaccination. Using a self-controlled design, incident diagnoses from inpatient and emergency department encounters were assessed for statistical clustering during post-vaccination risk windows within the tree-like structure of International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes. Two analyses using tree-based scan statistics were conducted: conditional tree-temporal, with moving risk and control windows of varying lengths within an 84-day period; and conditional Bernoulli, with pre-specified risk and control windows of 1-21 and 43-84 days post-vaccination, respectively. A statistically significant cluster was defined as a p-value < 0.01.
    RESULTS: We identified 1,042,847 PCV20 vaccinees. In the tree-temporal analysis, statistically significant clusters included codes for non-specific adverse effects of a vaccine or other medical product, within 7 days post-vaccination (p-value range: 0.0001-0.0059); fever, 1-2 days post-vaccination (p-value range: 0.0001-0.0004); cellulitis of the left upper limb, days 2-5 (p-value 0.0001); and hemorrhoids or perianal venous thrombosis, days 42-63 (p-value 0.0045). We also detected statistically significant clusters for non-specific adverse effects from vaccines via the Bernoulli analysis within 21 days post-vaccination (p-value range: 0.0001-0.0069). We reviewed individual-level data from a sample of patients in the cluster for hemorrhoids; hemorrhoids appeared to be either present before vaccination or found during routine colonoscopy.
    CONCLUSIONS: This untargeted scan for potential adverse events following PCV20 vaccination did not identify clusters of diagnoses representing new, serious safety concerns, though there was low power to detect an association with rare outcomes. The identified clusters were known vaccination-associated events in pre-licensure randomized controlled trials and prior observational analyses or unlikely to be associated with the vaccine.

  • Link to Article
    publication date
  • 2026
  • published in
  • Drug Safety  Journal